33. Consolidated companies as of 31 December 2023
Name of the subsidiary |
Country |
% voting right |
Change in % voting |
|---|---|---|---|
Continuing operations |
|
|
|
Glpg US Inc. (formerly AboundBio Inc.) |
United States |
100% |
|
Galapagos B.V. (merged with CellPoint B.V.) |
The Netherlands |
100% |
|
Galapagos GmbH |
Switzerland |
100% |
|
Glpg US Holding Inc. (formerly Galapagos Inc.) |
United States |
100% |
|
Galapagos NV |
Belgium |
Parent company |
|
Galapagos Real Estate Belgium BV |
Belgium |
100% |
|
Galapagos Real Estate Netherlands B.V. |
The Netherlands |
100% |
|
Galapagos SASU |
France |
100% |
|
Xenometrix, Inc. in liquidation |
United States |
100% |
|
|
|
|
|
Discontinued operations |
|
|
|
Galapagos Biopharma Belgium BV |
Belgium |
100% |
|
Galapagos Biopharma Netherlands B.V. |
The Netherlands |
100% |
|
Galapagos Biopharma Spain S.L.U. |
Spain |
100% |
|
Galapagos Biopharma Italy S.r.l. |
Italy |
100% |
|
Galapagos Biopharma Germany GmbH |
Germany |
100% |
|
Galapagos Biopharma Sweden AB |
Sweden |
100% |
|
Galapagos Biopharma Norway AS |
Norway |
100% |
|
Galapagos Biopharma Finland Oy |
Finland |
100% |
|
Galapagos Biopharma Denmark ApS |
Denmark |
100% |
|
Galapagos Biopharma Austria GmbH |
Austria |
100% |
|
Galapagos Biopharma Ireland Ltd |
Ireland |
100% |
|
Galapagos Biotech Ltd |
United Kingdom |
100% |
|
There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.